ImmunityBio reports 700% YoY revenue growth to $113M; first lung cancer approval in Saudi Arabia

ImmunityBio, Inc.

2025-FY EPS reported -$0.38 revenue$113,288,000

Full-year 2025 ANKTIVA net product revenue $113M (up ~700% YoY); Q4 net revenue $38.3M (up 431% YoY).
Unit sales volume increased 750% in 2025 vs 2024; cash and securities $242.8M as of Dec 31, 2025.
SFDA granted conditional accelerated approval for ANKTIVA + checkpoint inhibitors in metastatic NSCLC (Jan 2026) – first lung cancer approval globally.
Global regulatory footprint expanded to 33 countries across 4 jurisdictions (US, UK, EU, Saudi Arabia) in under two years.
Net loss attributable to common stockholders narrowed to $351.4M in 2025 from $413.6M in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.